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Abstract
AIM: To develop a risk model for Crohn’s disease (CD) 
based on homogeneous population.
METHODS: In our study were included 160 CD 
patients and 209 healthy individuals from Slovenia. 
The association study was performed for 112 single 
nucleotide polymorphisms (SNPs). We generated 
genetic risk scores (GRS) based on the number of risk 
alleles using weighted additive model. Discriminatory 
accuracy was measured by area under ROC curve 
(AUC). For risk evaluation, we divided individuals 
according to positive and negative likelihood ratios (LR) 
of a test, with LR > 5 for high risk group and LR < 0.20 
for low risk group.
RESULTS: The highest accuracy, AUC of 0.78 was 
achieved with GRS combining 33 SNPs with optimal 
sensitivity and specificity of 75.0% and 72.7%, 
respectively. Individuals with the highest risk (GRS > 
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Case Control Study
Multi-locus genetic risk score predicts risk for Crohn’s 
disease in Slovenian population
provided valuable insight into the genetic architecture of 
CD, thus helping us better understand the mechanisms 
of innate immunity (NOD2), mucosal integrity 
(IBD5), autophagy (ATG16L1, IRGM), lymphocyte 
differentiation and proliferation (IL23R, STAT3)[5-7]. 
Recent meta-analysis of data from 15 existing GWASs 
and an independent genotype set obtained from 
DNA microarray (Immunochip) enrolled 75000 IBD 
cases and controls from International Inflammatory 
Bowel Diseases Genetic Consortium (IIBDGC) and 
identified 71 novel variants for a total of 163 IBD loci. 
Of these loci, 110 conferred risk to both IBD subtypes, 
whereas 30 were unique to CD[8]. Several studies 
have investigated risk prediction for CD[9-12]. In CD the 
strongest known association is with the NOD2 gene, 
which was for some time considered to be a possible 
candidate for genetic screening but ultimately has not 
been accepted [an area under ROC curve (AUC) of 
0.56], because individual markers have small effect on 
risk and thus have poor predictive ability[13]. In addition, 
inclusion of only highly significant common variants 
with strong effect sizes (NOD2, IL23R, ATG16L1, IRGM) 
into a predictive model managed to improve predictive 
power but it was still insufficient for accurate prediction 
(AUC of 0.66)[10]. In recent studies, polygenic genetic 
risk scores (GRS) have been used to summarize risk-
associated alleles, weighted by their effect sizes (odds 
ratios) among an assemble of markers that do not 
individually achieve significance in association study 
since it has been suggested that a higher number of 
included variants with weak to moderate effect sizes 
can explain larger proportion of heritability[5,14].
Recently established 163 IBD loci now provide an 
important basis for genetic risk prediction. Attempts 
have been made to develop accurate genetic risk 
profiles based on a large number of patients from 
several population heterogeneous cohorts that were 
enrolled in IIBDGC[15]. However, limited data exist on 
developing genetic risk profiles in a single genetically 
homogeneous population.
We aimed to test the joint contribution of well-
established susceptibility loci, obtained from custom 
designed single nucleotide polimorphism (SNP) 
genotyping chip “Immunochip” (iCHIP)[8], in order to 




Study population consisted of 236 healthy individuals 
in the control group and 202 CD patients from the 
University Medical Center Ljubljana and Maribor as 
described previously[16]. All CD patients had reliable 
clinically and histopathologically confirmed disease. The 
study was approved by Slovenian National Committee 
for Medical Ethics (KME 80/10/07, 21p/12/07 and KME 
106/05/11). Patients gave informed consent prior to 
inclusion in the study and the study was performed 
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5.54) showed significantly increased odds of developing 
CD (OR = 26.65, 95%CI: 11.25-63.15) compared to 
the individuals with the lowest risk (GRS < 4.57) which 
is a considerably greater risk captured than in one SNP 
with the highest effect size (OR = 3.24). When more 
than 33 SNPs were included in GRS, discriminatory 
ability was not improved significantly; AUC of all 74 
SNPs was 0.76.
CONCLUSION: The authors proved the possibility of 
building accurate genetic risk score based on 33 risk 
variants on Slovenian CD patients which may serve as a 
screening tool in the targeted population.
Key words: Inflammatory bowel disease; Crohn’s 
disease; discriminatory accuracy; Genetic risk score; 
Single nucleotide polymorphisms
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Genome wide association studies have 
provided a comprehensive catalogue of susceptibility 
inflammatory bowel disease (IBD) loci, which now 
present an important basis for genetic risk prediction. 
We aimed to develop an accurate Crohn’s disease 
(CD) risk prediction model for the Slovenian cohort. 
The most optimal 33 SNPs model showed good 
discriminatory ability, which may be useful for risk 
stratification in targeted population (gastrointestinal 
disturbances, positive family history). Individuals in the 
highest risk group have 27-fold higher odds for CD risk 
compared to individuals in the lowest risk group. To 
the best of our knowledge, this is the first population 
specific genetic prediction based on recently established 
IBD loci.
Zupančič K, Skok K, Repnik K, Weersma RK, Potočnik U, 
Skok P. Multi-locus genetic risk score predicts risk for Crohn’s 
disease in Slovenian population. World J Gastroenterol 2016; 
22(14): 3777-3784  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v22/i14/3777.htm  DOI: http://dx.doi.
org/10.3748/wjg.v22.i14.3777
INTRODUCTION
Crohn’s disease (CD) is a multifactorial chronic inflam­
matory bowel disease (IBD) caused by dysregulated 
immune response to commensal intestinal microflora 
in genetically susceptible individuals[1]. CD can affect 
any segment of the gastrointestinal tract and has a 
relapsing-remitting course with various patterns of 
behavior[2,3]. Prevalence and incidence of CD increased 
significantly over the last decades in developed parts of 
the world and ranges from 136 to 319 per 100000 and 
from 6 to 29 per 100000, respectively, indicating its 
emergence as a global disease[4].
Genome-wide association studies (GWASs) have 
in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki). 
SNP selection
Genotyping data for cases and controls was obtained 
from the iCHIP, where Slovenian patients and controls 
were enrolled within the IIBDGC. Genotyping for initial 
236 controls and 202 CD patients was performed 
with hybridization on iCHIP according to protocol 
(Illumina). Rigorous quality control of the study group 
(gender matching, call rate, family ties and genetic 
origin verification) and genotyping information [Hardy­
Weinberg equilibrium (HWE)] was applied in PLINK 
v1.07 and R. Individuals with more than 10% missing 
genotypes were excluded. SNPs with a call rate below 
90% were discarded from further analyses. We also 
excluded SNPs when the controls showed deviation 
from HWE with a P < 0.0001 in control group. The 
remaining 160 CD patients, 209 controls, and 112 
SNPs from a total of 163 SNPs were included in further 
statistical analysis.
Statistical analysis
The case­control association analysis of allele 
frequencies was statistically assessed in SPSS 22.0 
(IBM Corp., Armonk, NY) using Fischer exact test and 
χ 2. The results were presented as P-values, OR and 
95%CI. We compared risk alleles and their frequencies 
to those in meta-analysis study by Jostins et al[8] and 
included only those SNPs from a total of 112 SNPs 
that showed association of risk allele with Slovenian 
CD patients risk allele. Statistical significant threshold 
(P­value) was at 0.05 and 4.46 × 10-4 after Bonferroni 
correction for multiple testing. 
Genetic risk profiles construction 
We constructed GRS in an additive manner using a 
weighted approach. The number of risk alleles at each 
locus (2, 1, 0) was multiplied by their corresponding 
beta-coefficients of effects sizes [log(OR)] and then 
summed up in GRS that each individual carried. In 
order to avoid bias we used ORs from recent meta-
analysis by Jostins et al[8].
For optimal risk construction, we used a ranking 
P-values approach, starting with SNP with the lowest 
P-value and gradually adding one per one in GRS[17]. 
The most optimal GRS was then compared to GRS of 
the remaining SNPs, to GRS of marginally significant 
SNPs with highest OR and to GRS of all included SNPs. 
ROC with AUC were used to measure discriminatory 
accuracy at various GRS cut-offs (sensitivity/1-
specificity). An area of an AUC < 0.7 represents poor 
discrimination; 0.7-0.8 acceptable (fair) discrimination, 
and 0.8-0.9 excellent discrimination[18]. Cut-off 
values for sensitivities, specificities, positive/negative 
predictive values and positive/negative likelihood ratios 
were computed in Medcalc 14.8. Likelihood ratio (LR) 
describes how likely an affected person is going to 
have a disease compared to a healthy person with 
the same result according to a given test (positive or 
negative). A positive LR above 5 is considered to be 
a moderate evidence to confirm a disease, LR above 
10 strongly confirms a disease, whereas a negative 
LR below 0.2 is considered moderate, and below 0.1 
strong evidence to exclude disease. LR are powerful 
tools for GRS evaluation since they are not affected by 
a prevalence and with prior probability (prevalence) 
they present a basis for post-test probability (predictive 
value - PV) calculation[19]. Positive PV presents the 
probability of patient having a disease if the test is 
positive, while the opposite is true for a negative 
PV[20]. For post-test probabilities estimations, we 
used prevalence of disease 1.2/1000, since there are 
approximately 2000-2500 CD patients in Slovenia.
Statistical analysis of distribution (normal, non-
parametric) of selected parameters (GRS, allele 
frequencies, OR, United States) between cases and 
controls, and between different GRS models was 
conducted with Shapiro-Wilk test in SPSS 22.0. t-test 




We found that risk alleles frequencies of 74 SNPs (66%) 
matched with those in the reference study by Jostins 
et al[8]. The risk alleles of remaining 38 SNPs were in 
the opposite direction and therefore we excluded them 
from further analysis (Supplement Table 1). This was 
to be expected since our case-control group was too 
small to achieve sufficient statistical power comparing 
to 75.000 cases and controls enrolled in IIBDGC[8]. In 
present study, we initially confirmed 15 statistically 
significant associations (for dominant, recessive, allelic 
model) from a total of 74 SNPs; among these 15 
significant associations, only 8 SNPs were statistically 
significant under allelic model (Supplement Table 1). 
None of them remained significant (P < 4.46 × 10-4) 
after Bonferroni correction.
Genetic risk profiles 
We used the ranking P-value method for GRS 
construction as described in the methods section. For 
individual SNPs, AUC ranged from 0.50 to 0.57 (median 
0.53) for SNPs with the lowest effects sizes versus 
SNPs with the highest effect sizes, respectively, but the 
difference between these two most distant AUC values 
was not significant (P = 0.06). Significantly better 
(P < 10-4) discriminatory ability than in an individual 
marker was achieved when 8 nominally significant 
SNPs (P < 0.05) were included in a model with AUC 
of 0.69 (95%CI: 0.64­0.74). Their ORs ranged from 
1.42 to 3.24 (median 1.50). The most optimal GRS 
was achieved with 33 SNPs model with AUC of 0.78 
(95%CI: 0.72­0.82) and ORs ranging from 1.15 to 
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(Table 1). Due to the low CD prevalence (0.12%) only 
up to 1.5% of population would be correctly confirmed 
as diseased. On the contrary, high-risk individuals 
(positive family history, gastrointestinal disturbances) 
with estimated pre-test probability of 10% have up to 
59.1% higher probabilities of having the disease if they 
test positive. 
To evaluate risk between individuals in our study, 
we divided them into three risk groups according to 
optimal positive and negative LRs at corresponding GRS 
cut-offs. LR are powerful tools for model evaluation, 
since they do not depend on prevalence (for further 
readings see Methods). The high­risk group included 
individuals who tested above GRS cut-off 5.54 (positive 
LR > 5.0). The intermediate group (grey zone) included 
individuals with GRS between 4.57 and 5.54 and the 
low risk group included individuals who tested below 
GRS cut­off 4.57 (negative LR < 0.20). The results 
showed that the odds of developing CD (OR = 26.65, 
95%CI: 11.25­63.15) were significantly increased 
in individuals in the highest risk group compared to 
individuals in the lowest risk group (Table 2). 
Since the majority of the tested individuals fall 
into the “grey zone” category (intermediate risk 
group) (Figure 2) it would be useful to further stratify 
3.24 (median 1.32). It performed significantly better 
(P = 8 × 10-4) than the 8 SNPs model, although the 
8 SNPs model had higher ORs median (P = 0.0012). 
Interestingly, mean risk allele frequencies (RAF) of 
included SNPs did not differ significantly between 8 
SNPs and 33 SNPs risk models (P = 0.110). 
When more than 33 SNPs were included in GRS 
(Figure 1), discriminatory ability was not improved 
significantly; AUC of all 74 SNPs was 0.76. These 
additional SNPs present needless background noise. To 
confirm this, we also tested accuracy of the remaining 
41 SNPs, which achieved poor performance with AUC 
of 0.58 (95%CI: 0.53­0.63) and this value is similar to 
an accuracy of an individual SNP. The 41 SNPs model 
accuracy and median of ORs (ranging from 1.00 to 
1.85; median 1.11) of SNPs were significantly lower 
than in the aforementioned 33 SNPs model (P < 10-4). 
RAF of the included SNPs did not differ significantly 
between these two models (P = 0.288).
Evaluation of 33 SNPs genetic risk model 
We presented the applicability of GRS in context of 
pre-test (prevalence), LR, and corresponding post-test 
probability of target population for two different prior 
probabilities (general population, high-risk population) 
3780 April 14, 2016|Volume 22|Issue 14|WJG|www.wjgnet.com
Table 1  Genetic risk profile based on the genetic risk score in 33 single nucleotide polymorphisms model
GRS Sensitivity Specificity +LR -LR +PV -PV +PV1 -PV1
> 4.27 98.12% 19.62%   1.22 0.10 0.15% 100.00% 11.94% 98.95%
> 4.57 93.12% 34.45%   1.42 0.20 0.17%   99.98% 13.63% 97.83%
> 5.05 75.00% 72.73%   2.75 0.34 0.33%   99.96% 23.41% 96.32%
> 5.54 35.63% 93.30%   5.32 0.69 0.63%   99.92% 37.14% 92.88%
> 5.81 10.00% 99.04% 10.42 0.91 1.24%   99.89% 53.65% 90.83%
> 5.94   6.25% 99.52% 13.02 0.94 1.54%   99.89% 59.13% 90.53%
1PV-positive and negative predictive value for estimated prevalence of CD in targeted population with high risk (10%). LR-positive and negative likelihood 
ratio, PV-positive and negative predictive value for estimated prevalence of CD in Slovenian population (0.12%). GRS: Genetic risk scores; CD: Crohn’s 

















































































































AUC for different P -values thresholds
Figure 1  Area under curve for different P-values thresholds and corresponding numbers of included single nucleotide polymorphisms. The most optimal 
AUC was achieved with GRS of 33 risk alleles (AUC of 0.78) at P-value threshold of 0.256 (marked with *). Adding 41 SNPs to GRS did not improve GRS significantly, 
however it presented needless background noise. AUC: Area under curve; GRS: Genetic risk scores; SNPs: Single nucleotide polymorphisms.
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these individuals. According to the best trade-off 
between sensitivity and specificity we can set GRS 
cut­off at 5.05 (sensitivity 75.0%, specificity 72.7%, 
+LR 2.45), where in high risk population 23.4% 
subjects will be identified as diseased if they are tested 
positive (Figure 3). Individuals, who test below the 
cut­off 5.05, have a high probability of 96.5% that 
they are not affected. 
Moderately better risk stratification (+LR > 5, high 
risk group) can be achieved by setting the threshold 
to GRS cut­off 5.54 with specificity of 93.3% but at 
expense of higher number of false negatives (sensitivity 
of 35.6%) (Figure 4). By setting the threshold even 
higher (GRS > 5.80) it is possible to yield positive 
LR greater than 10% and 53.7% individuals will be 
classified as diseased. 
More precise CD exclusion can be achieved with 
lower GRS cut-off (< 4.57), where we can rule out 
non­diseased individuals with a sensitivity of 93.12% 
and a negative PV of 97.8% but at an expense of 
having more false positives (specificity of 34.65%). 
DISCUSSION
In our study, we developed an accurate CD risk 
prediction model for Slovenian cohort. To the best of 
our knowledge, this is the first population specific 
genetic prediction based on recently established 
IBD loci. The most optimal 33 SNPs model showed 
good discriminatory ability (AUC of 0.78), which may 
be useful for risk stratification in targeted population. 
Individuals in the highest risk group (GRS > 5.54) 
have 27-fold higher OR for CD risk compared to 
individuals in the lowest risk group (GRS ≤ 4.57). This 
is considerably greater risk captured than in individual 
SNP with the highest effect size (IL23R, OR = 3.24). 
The highest discriminatory ability of individual SNPs 
yielded only 0.57 at best, which support findings from 
study by Jakobsdottir et al[10], that “individual markers 
are poor classifiers even with replicated high effect 
sizes”. 
According to literature, genetic risk prediction in 
CD using common risk loci ranges from AUC of 0.56 
to 0.72[10-12]. Recently it has been suggested that 
robust machine­learning techniques using large sample 
sizes and wider variant spectrum (including risk allele 
frequencies less than 0.05) in low linkage disequilibrium 
importantly improves risk prediction in CD to an 
AUC greater than 0.85[15,17]. Theoretically, given its 
high heritability (not accounting the low prevalence 
of CD), it is possible to achieve AUC up to 0.98 if all 
CD risk loci have been identified and effect sizes are 
accurately measured[21,22]. However, these studies 
are technologically complex and are mostly based on 
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Table 2  Comparison of risk in different groups of individuals
Group OR P  value 95%CI
High vs low risk 26.65 < 0.0001 11.25-63.15
High vs intermediate risk   4.06 < 0.0001   1.32-12.47
Intermediate vs low risk   5.13 < 0.0001 2.76-9.56
High-risk group: GRS > 5.54; Intermediate risk group: 4.57 < GRS ≤ 5.54; 


























Figure 2  Distribution of Genetic risk scores in Crohn’s disease and 
controls. GRS is normally distributed (Shapiro-Wilk, P > 0.05) in CD cases and 
controls. Cases have significantly higher GRS (5.32 ± 0.47) than controls (4.78 















Figure 3  Flow diagram for sensitivity (75%) and specificity (72.7%) in 
targeted population (Crohn’s disease prevalence 10%). If we test 100 
subjects and set the cut-off at 5.05, 32 of them will test positive (above cut-off), 















Figure 4  Flow diagram for sensitivity (35.6%) and specificity (93.3%) 
in targeted population (Crohn’s disease prevalence 10%). If we test 100 
subjects and set the cut-off at 5.54, 10 of them will test positive (above cut-off), 
with post-test probability of disease approximately 40% (4/10).
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simulation data and/or require large and heterogeneous 
patients’ cohorts data which is not always available. In 
our study, in order to avoid methodologic complexity, 
we used a simplified P-value ranking approach to deter-
mine optimal number of SNPs, as already described in 
Methods[17].
Studies have shown that Europe is genetically and 
ethnically diverse. Genetic differentiation exists not 
only between the northwest and southeast part of the 
continent but also within these two distinct groups, 
creating indispensable inter-population differences[23,24]. 
In this case SNPs may serve as proxies for shared 
environments that can differ from population to 
population. This may be due to interference of different 
factors modifying genetic architecture (geographical 
placement, pollutants, adherence to particular diet, 
etc.)[25]. Therefore, population specific risk profiles may 
offer a more accurate risk estimation for the selected 
population, which was one of the main reasons why we 
included the small homogeneous Slovenian cohort[26]. 
A genetic risk model may be primarily useful 
for screening purposes in a population with higher 
prior probabilities of CD; prolonged gastrointestinal 
disturbances suggestive of CD (abdominal pain, 
diarrhea, weight loss) and/or positive family history 
to identify at-risk individuals for further more invasive 
diagnostic procedures. In addition to sufficiently high 
prevalence, a risk prediction model also needs to be 
sensitive and specific with considerably high positive 
and negative likelihood ratios and cost efficient (as few 
markers as possible)[19,20,27]. The prevalence of CD in 
patients with one affected first­degree relative ranges 
from 2.2% to 16.2%[28]. For Slovenia, there is currently 
no accurate data for family history in CD patients 
available, however it has been clinically estimated 
that around 10% of CD patients have one affected 
first-degree relative. In this case, positive post-test 
probability rises up to 59.1% compared to general 
population, where positive post-test probability due to 
low CD prevalence yields only 1.5% at best. According 
to our results, the most optimal cut-off was at GRS > 
5.05 with sensitivity of 75.0% and specificity of 72.7%. 
By raising cut-off to a higher GRS > 5.54 it is possible 
to stratify at-risk individuals even more precisely with a 
specificity of 93.3% but at expense of lower sensitivity 
(35.6%) and therefore a higher number of false 
negatives. However, due to small number of individuals 
who test positive (Figure 4) it may be more cost-
effective and practical than setting cut-off to a lower 
GRS. For comparison, prostate-specific antigen test 
yields similar results with sensitivity and specificity of 
20.5% and 93.6%, respectively and is widely used in 
screening for prostate cancer[29].
To compare risks between high and low risk group, 
GRS of individuals are usually divided into quartiles 
or quintiles. However, this approach may be too rigid 
and therefore may not present all true observations 
of the series[18]. We thereby propose a more suitable 
approach, by using test likelihood ratios, which are 
powerful tools for the GRS evaluation[19]. In our case 
we divided individuals into three groups according to 
moderate increase in likelihood of disease (+LR > 5.0; 
-LR < 0.20) because of a better trade-off between 
sensitivity and specificity (less false negatives). 
Individuals in the highest risk group had 27-fold higher 
OR for CD risk compared to individuals in the lowest 
risk group. Similar results with high OR between 
risk groups were presented in rheumatoid arthritis 
GRS study by Yarwood et al[27] (OR = 27.13), and in 
psoriasis GRS study by Yin et al[30] (OR = 28.20) but 
they used quintiles and quartiles, respectively. Since 
LR higher than 10 is largely conclusive for disease, in 
our case it is possible to yield even 55-fold higher OR 
for CD risk compared to individuals, but at expense of 
higher number of false negatives (sensitivity 10%).
Our results also highlight the importance of testing 
published SNPs in population cohort before building 
models. For example, when all 112 SNP were included 
in the model we achieved an AUC of only 0.64, since 
risk alleles were labelled according to reference 
study by Jostins et al[8] and 38 were in the opposite 
directions than those in the reference study.
It has been suggested that including a higher 
number of risk variants with weak to moderate effect 
sizes, that were not all significant in the association 
study, can improve risk prediction on account of ex-
plaining larger proportion of heritability[14,31]. Intere-
stingly, when additional 41 SNPs with weak ORs were 
included to the model of 33 SNPs the discriminatory 
ability did not improve significantly. In our case, these 
SNPs actually present only a background noise and are 
therefore cost redundant. The discriminatory accuracy 
of 41 SNPs was in fact similar to an accuracy of an 
individual SNP, which represents a poor classifier (no 
better than a chance). Therefore, a cluster of higher 
numbers of non-significant variants with very weak 
effect sizes may also explain only a minor proportion 
of genetic variance in complex diseases (the same as 
individual SNP). Currently, 163 IBD loci accounts for 
13.6% of total CD heritability[8]. Future discovery of 
rare variants with lower frequencies and high effect 
sizes through robust gene-mapping studies (next-
generation sequencing) could lead to improvement of 
“missing heritability” and to more accurate genetic risk 
prediction[22,31].
A limitation of our study is a small number of CD 
patients and controls. Therefore, results may be biased 
due to over­fitting and should be validated on a larger 
case-control sample size. Furthermore, we analyzed 
only common risk loci from iCHIP, which were strongly 
confirmed on a large IIBDGC heterogeneous cohort 
thus balancing out possible inter-population genetic 
variations. It would be interesting to test, if other 
variants which have not reached genome-wide levels of 
significance could improve our population specific risk 
prediction. And lastly, we used additive model which 
does not account for possible gene-gene interactions.
In conclusion, to the best of our knowledge, this is 
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the first population specific study developing predictive 
models after the 163 IBD SNPs have been discovered[8]. 
Population specific genetic models may offer more 
optimal risk stratification for selected population than 
ethnically and genetically diverse consortiums. In our 
study we presented “real” issues of small populations, 
a simpler methodology approach with ranking P-values 
and a comprehensible transition to clinical scenario.
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loci. Their results suggest that it is possible to construct a genetic risk model 
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disease (CD).
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The genetic risk model may serve as a screening tool in a targeted population 
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further improve their population specific genetic risk prediction.
Terminology
Immunochip is an Illumina Infinium single-nucleotide polymorphism (SNP) 
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different immune-mediated diseases including CD and ulcerative colitis. This 
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